免疫检查点抑制剂用于局部进展期胃癌新辅助治疗研究进展  

Research progress of immune checkpoint inhibitors in neoadjuvant therapy of locally advanced gastric cancer

作　　者：赵雪松 高志冬[1,2] 周静[1] 叶颖江[1,2] ZHAO Xue-song;GAO Zhi-dong;ZHOU Jing(不详;Department of Gastroenterological Surgery,Peking University People′s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院胃肠外科,北京100044 [2]北京大学人民医院外科肿瘤研究室,北京100044

出　　处：《中国实用外科杂志》2023年第4期453-460,共8页Chinese Journal of Practical Surgery

基　　金：国家自然科学基金(No.81871962)。

摘　　要：免疫检查点抑制剂(ICIs)在胃癌治疗中的应用不断前移,为新辅助治疗带来了新的选择。局部进展期胃癌新辅助免疫治疗效果研究结果显示,新辅助ICIs联合治疗方案展现出较好的效果,可能在现有基础上进一步提升疗效。对于特定人群,免疫治疗联合靶向治疗或新辅助“双免”治疗可能展现优势。由于免疫相关毒性反应,对ICIs的使用应谨慎,如何筛选免疫治疗的受益人群,挑选最佳治疗方案,仍是面临巨大挑战。期待后续Ⅲ期临床研究结果能够揭示ICIs在胃癌新辅助治疗中的真正效果,使免疫治疗取得新的突破,进一步改善胃癌病人生存。Immune checkpoint inhibitors(ICIs)continue to advance in gastric cancer,which bringing new options for the neoadjuvant treatment.Throughout the current research on neoadjuvant immunotherapy for locally advanced gastric cancer,ICIs in combination with chemotherapy/radiotherapy neoadjuvant therapy have shown good therapeutic efficacy and may further enhance the efficacy on the existing basis.For specific populations,immunotherapy combined with targeted therapy or dual-immune neoadjuvant therapy may show advantages.Due to immune-related toxicity,the use of immune checkpoint inhibitors should be cautious,and it remains a great challenge to screen the beneficiaries of immunotherapy and select the best treatment options.It is expected that the subsequent phaseⅢclinical studies will reveal the true effect of ICIs in neoadjuvant treatment of gastric cancer,leading to a new breakthrough in immunotherapy in gastric cancer and further improving the survival of gastric cancer patients.

关 键 词：局部进展期胃癌 免疫治疗 免疫检查点抑制剂 新辅助治疗 

分 类 号：R6[医药卫生—外科学]